(NASDAQ: PASG) Passage Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.57%.
Passage Bio's earnings in 2026 is -$45,522,000.On average, 9 Wall Street analysts forecast PASG's earnings for 2026 to be -$28,071,545, with the lowest PASG earnings forecast at -$44,721,683, and the highest PASG earnings forecast at -$10,205,648. On average, 7 Wall Street analysts forecast PASG's earnings for 2027 to be -$27,112,731, with the lowest PASG earnings forecast at -$60,113,076, and the highest PASG earnings forecast at -$7,612,133.
In 2028, PASG is forecast to generate -$31,194,028 in earnings, with the lowest earnings forecast at -$79,204,357 and the highest earnings forecast at -$5,557,531.